Madrigal Pharmaceuticals, Inc. MDGL Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s accrued liabilities, current?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported accrued liabilities, current of $275.76M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s accrued liabilities, current changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s accrued liabilities, current increased by 122.1% year-over-year, from $124.17M to $275.76M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s accrued liabilities, current?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s accrued liabilities, current has grown at a 41.9% compound annual growth rate (CAGR), from $45.22M to $260.39M.